Citations

Clear

4564 citation(s) found for "Yu, Virginia".

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3
Luger, Selina M. , Pratz, Keith W. , Perl, Alexander E. , Altman, Jessica K. , Redner, Robert L. , Qasrawi, Ayman , Asch, Adam S., Jeyakumar, Deepa , Foran, James M. , Kolitz, Jonathan E. , Berman, Ellin , Wilde, Lindsay , Abedin, Sameem , Gundabolu, Krishna , O’Dwyer, Kristen M. , Curran, Emily , Ross, Kelly , Sun, Zhuoxin , Litzow, Mark R. , Abedin, Sameem , Chen, Li , Loghavi, Sanam , Fathi, Amir T , Shah, Meera , Kota, Vamsi , O'Dwyer, Kristin , Kishtagari, Ashwin , Litzow, Mark R.

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 221-221

10.1182/blood-2024-201595 Get It

Background: The addition of midostaurin (M), an oral multi-kinase inhibitor, to intensive chemotherapy (IC) prolongs survival in newly diagnosed (ND) FLT3 mutated (m) AML. It is not known if there is a benefit to more potent and selective FLT3 inhibitors. Among these is Gilteritinib (G), now approved as a single agent in relapsed/refractory FLT3m AML. Combined with IC, G also leads to high measurable residual disease (MRD)negative (-) composite complete remission (CRc) in FLT3 Internal Tandem Duplication (ITD)m AML. The aim of the PrECOG 0905 study was to compare FLT3m clearance and CRc rates of G vs M with IC in adults with ND FLT3m AML. Methods: We conducted a randomized, open-label, phase 2 trial comparing G to M in combination with IC during induction and consolidation in ND AML pts with centrally PCR detected FLT3 ITD or TKD mutations. Pts age 18-70 with non M3 AML and no known core binding factor rearrangement were eligible. Pts were stratified by mutation type (TKD only vs. ITD (+/- TKD)), NPM1 mutation status, and FLT3-ITD allelic ratio. Induction consisted of cytarabine 100 mg/m2 by continuous infusion daily, on day (d) 1-7 and daunorubicin 90 mg/m2 IV on d 1-3. G 120 mg daily or M 50 mg twice daily was given orally on d8-21. Consolidation (up to 4 cycles) began within 60 d of induction with Cytarabine (1.5-3 g/m2 IV) X 6 doses and G or M (as per randomization) on d8-21. Pts could proceed to transplant (HCT) at any time. Maintenance was not included. The primary outcome was FLT3m MRD (-) CRc after induction. MRD for TKD mutations was tested by PCR (sensitivity 10-2); ITD MRD was tested by amplicon-based NGS (sensitivity 10-4). Safety and efficacy were analyzed in all eligible pts who received treatment. Secondary endpoints included comparison of CRc, MRD by flow cytometry (sensitivity 10-3), and survival. Results: From 11/2019 to 11/2022, 722 pts were screened at 37 centers, 180 pts randomized, and 177 pts (58% female, 77% white, 8.5% black, 8.5% hispanic) treated on the G (n=90) or M (n=87) arm. Median age was 54, with 27.7% > age 60. FLT3-ITD was present in 80% in the G arm and 78.2% in the M arm. Of those with FLT3-ITD, NPM1 was detected in 56.9% pts in G arm and 58.8% in M arm. 24.4% G and 20.7% M pts had co-occuring FLT3-ITD, NPM1 and DNMT3A mutations. Adverse karyotype was seen in 3.4% G and 9.3% M while 10% G and 13.8% M were ELN 2022 adverse risk. For pts on G arm, 85.6% achieved CRc compared to 72.4% for M (p=0.042). 5 (5.6%) pts on G arm and 6 (6.9%) on M arm received 2 cycles in induction. Post induction, the FLT3m- CRc rate was 40% for G vs 47.1% for M (p=0.366). FLT3-TKD only mutated pts achieved CRc in 88.9 % with G and 63.2% with M and FLT3m- CRc in 72.2% and 63.2% respectively. FLT3-ITDm (+/- TKDm) pts achieved CRc/FLT3m- CRc in 84.7%/31.9% with G and 75%/42.6% with M, respectively. In pts with FLT3-ITD, NPM1 and DNMT3A mutations, 95.5% G and 72.2% M achieved CRc and 50% G vs 33.3% on M achieved FLT3m- CRc. Flow cytometry MRD negative CRc was documented in 64.4% on G arm and 59.8% on M arm after induction (p=0.539). On G arm 67 (74%) patients received at least one cycle of consolidation compared to 53 (61%) pts on M arm. On exploratory analysis, 54 (66%) G and 40 (46%) M were reported to proceed to HCT in first remission. FLT3m testing was done post consolidation cycle 1 in 27 pts in FLT3m+ CRc after induction and 15/18 (83%) on G and 4/9 (44.4%) on M converted to FLT3m-. On multivariate logistic regression analysis for FLT3m-CRc post-induction, FLT3-ITD allelic ratio, NPM1m, WBC and hemoglobin at baseline were significant at the 0.10 two-sided level, while treatment arm, and 2017 ELN risk were not. There were no deaths from treatment-related (TR) adverse events (TRAEs) while grade >=3 TRAE was reported in 73%G vs 70% M during induction and 79%G vs 73%M pts during consolidation. Conclusion: Induction therapy with daunorubicin 90 mg/m2 X 3 days, cytarabine 100 mg/m2 and gilteritinib results in an excellent CRc rate with no TR deaths in pts with ND FLT3m AML up to age 70. Compared to M, G increased the CRc but not the FLT3m- CRc rate after induction. More post induction FLT3m+CRc pts who received G became FLT3m- after consolidation cycle 1 and more G pts succeeded in proceeding to HCT. Future survival data will help evaluate the clinical impact of G and MRD assessments in ND FLT3mAML. Larger studies will be needed to establish most predictive timing of MRD and for definitive comparisons of these drugs in patients with specific mutation profiles ( ie TKD, ITD/NPM1/DNMT3).
SOPRANO: Macitentan in patients with pulmonary hypertension following left ventricular assist device implantation
Frantz, Robert P. , Desai, Shashank , Ewald, Gregory A. , Franco, Verónica , Hage, A., LaRue, Shane , Mathier, Michael A., Mandras, Stacy A. , Park, Myung H., Wang, I‐Wen , Zolty, Ronald , Rendon, G. Gomez, Rocco, Mark A., Selej, Mona , Zhao, Carol, Schilling, Joel D , Frantz, Robert P , Horn, Evelyn M. , Ravichandran, Ashwin Kumar , Rame, J. Eduardo

Mayo Clinic

Pulmonary Circulation | December 4, 2024 | Volume: 14 | Issue: 4 | Pages: No page available

10.1002/pul2.12446 | PMID 39635465 Get It

AbstractMacitentan is a dual endothelin receptor antagonist (ERA) approved for treating pulmonary arterial hypertension (PAH). SOPRANO evaluated the efficacy and safety of macitentan versus placebo in pulmonary hypertension (PH) patients after left ventricular assist device (LVAD) implantation. SOPRANO was a phase 2, multicenter, double‐blind, randomized, placebo‐controlled, parallel‐group study. Patients with an LVAD implanted within the prior 90 days who had persistent PH (i.e., mean pulmonary arterial pressure ≥25 mmHg, pulmonary artery wedge pressure [PAWP] ≤18 mmHg, and pulmonary vascular resistance [PVR] >3 Wood units [WU]) were randomized (1:1) to macitentan 10 mg or placebo once daily for 12 weeks. The primary endpoint was change in PVR. Secondary endpoints included change in right‐heart catheterization hemodynamic variables, N‐terminal prohormone of brain natriuretic peptide levels, World Health Organization functional class, and safety/tolerability. Fifty‐seven patients were randomized to macitentan (n = 28) or placebo (n = 29). A statistically significant reduction in PVR from baseline to Week 12 was observed with macitentan versus placebo (placebo‐corrected geometric mean ratio, 0.74; 95% confidence interval, 0.58–0.94; p = .0158). No statistically significant differences were observed in secondary endpoints. In a post‐hoc analysis, 66.7% of patients receiving macitentan achieved PVR <3 WU versus 40.0% receiving placebo (p = .0383). Macitentan was generally well tolerated; adverse events were consistent with those in previous PAH studies with macitentan. In conclusion, macitentan showed promising tolerability and significantly reduced PVR in PH patients with persistently elevated PVR after LVAD implantation. ClinicalTrials. gov identifier: NCT02554903.
Forecasting Alcohol‐Related Liver Disease Mortality Trends in Younger Populations Using Advanced Time‐Series Models: A 1999–2030 Analysis
Ali, Hassam , Blaney, Hanna , Dahiya, Dushyant Singh , Gangwani, Manesh Kumar , Patel, Pratik , Jaber, Fouad , Satapathy, Sanjaya K. , Dahiya, Dushyant Singh , Sathapathy, Sanjaya , Jahagirdar, Vinay , Hayat, Umar , Simonetto, Douglas A.

Mayo Clinic

JGH Open | December 4, 2024 | Volume: 8 | Issue: 12 | Pages: No page available

10.1002/jgh3.70057 | PMID 39634629 Get It

ABSTRACTObjectiveAlcohol‐related liver disease (ALD) has emerged as a significant public health concern, particularly among younger populations. ALD remains the leading cause of alcohol‐attributable deaths. This study aims to forecast ALD mortality trends up to 2030, focusing on individuals under 55 years.MethodsWe utilized data from the CDC WONDER database (1999–2022) to examine ALD‐related deaths, identified by ICD‐10 codes (K70.0–K70.9). Crude mortality rates (CMRs) per 100 000 were analyzed and temporal trends were assessed using annual and average annual percent changes (APC/AAPC) with empirical quantile confidence intervals. An Autoregressive Integrated Moving Average (ARIMA) model was employed to project mortality rates until 2030, validated through time series cross‐validation.ResultsFrom 1999 to 2022, there were 181 862 ALD‐related deaths among individuals under 55, with mortality rates increasing from 3.9 per 100 000 in 1999 to 9.7 per 100 000 in 2022 (AAPC 4.66%, 95% CI: 3.90%–5.86%). Projections suggest rates will continue to rise, reaching 14.4 per 100 000 by 2030. From 1999 to 2022, the 25–34 age group experienced the highest increase, with an AAPC of 10.27% (95% CI: 9.19%–11.35%), while the 35–44 and 45–54 age groups showed more moderate increases, with AAPCs of 5.03% and 4.38%, respectively. Projections indicate an AAPC of 3.86% for ages 25–34, 3.90% for ages 35–44, and 6.17% for ages 45–54 by 2030.ConclusionForecasts indicate a continued rise in ALD mortality among individuals under 55, necessitating immediate public health strategies to mitigate this trend.
Dynamic associations between adverse events after lung transplantation and allograft ischaemic time
Zhang, Wenxi , Qiu, Tong, Metelmann, Isabella , Rucker, A. Justin , Du, Wenxing , Sef, Davorin , Jiao, Wenjie , Fritz, Ashley V, Sef, Davorin , Fritz, Ashley Virginia

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | December 3, 2024 | Volume: 66 | Issue: 6 | Pages: No page available

10.1093/ejcts/ezae425 | PMID 39626309 Get It

Abstract OBJECTIVES The effect of allograft ischaemic time (AIT) on postoperative events after lung transplantation remains unclear. This study aims to assess the feasibility of extending the duration of AIT. METHODS The United Network for Organ Sharing database was queried for adult lung transplantation from 4 May 2005 to 30 June 2020. Patients were divided as per AIT into standard ischaemic time (&lt;6 h) and prolonged ischaemic time (≥6 h) groups using propensity score matching and evaluated on a continuous scale using restricted cubic splines. The primary outcome was overall 1-year and 5-year survival. RESULTS Among 11 438 propensity-matched recipients, standard ischaemic time and prolonged ischaemic time showed no differences in overall 1-year (P = 0.29) or 5-year (P = 0.29) survival. Prolonged ischaemic time independently predicted early postoperative ventilator support for &gt;48 h (OR = 1.33, 95% CI 1.22–1.44), dialysis (OR = 1.55, 95% CI 1.30–1.84), primary graft dysfunction (PGD; OR = 1.28, 95% CI 1.09–1.50), acute rejection (OR = 1.42, 95% CI 1.24–1.62), and interestingly, decreased 5-year bronchiolitis obliterans syndrome (HR = 0.91, 95% CI 0.85–0.97). In relative risk curves, 1-year mortality, prolonged ventilation, dialysis and PGD steadily increased per hour as AIT extended. The risk of acute rejection and 5-year bronchiolitis obliterans syndrome also showed significant changes between 5 and 8 h of AIT. In contrast, 5-year mortality remained constant despite rising AIT. CONCLUSIONS Prolonged AIT worsened early outcomes such as PGD, but improved bronchiolitis obliterans syndrome freedom at later time points. Despite this, both short- and long-term survival were similar between prolonged ischaemic time and standard ischaemic time patients. Dynamic risk changes in post-transplant events should be noted for prolonged ischaemia lung use.
RETRACTED: Targeting mechanistic target of rapamycin complex 2 attenuates immunopathology in systemic lupus erythematosus
Ai, Minji , Jafar‐Nejad, Paymaan , Li, Yanfeng , Gades, Naomi M. , Alexander, Mariam P., Duarte‐García, Alí , Zeng, Hu , Alexander, Mariam P. , Gades, Naomi, Alexander, Mariam P , Bautista-Vargas, Mario, Duarte-García, Alí , Zeng, Hu , Zhou, Xian , Carrer, Michele , Bautista-Vargas, Mario Alejandro

Mayo Clinic

Rheumatology | December 3, 2024 | Volume: 64 | Issue: 6 | Pages: 3964-3974

10.1093/rheumatology/keae662 | PMID 39656824 Get It

RSV Vaccine with Nanoparticle-Based Poly-Sorbitol Transporter (PST) Adjuvant Improves Respiratory Protection Against RSV Through Inducing Both Systemic and Mucosal Humoral Immunity
Jung, Seong-Mook , Park, Young Chae, Seo, Eun Suk, Kim, Cheol Gyun , Kim, Taewoo , Yun, Cheol‐Heui , Shim, Byoung-Shik, Cheon, In Su , Son, Young Min , Yun, Cheol-Heui , Kim, Soo Ji , Seo, Eun Sang, Lee, Sumin , Cho, Eunjin, Chang, Jun , Shim, Byoung-Shik

Mayo Clinic

Vaccines | December 2, 2024 | Volume: 12 | Issue: 12 | Pages: 1354

10.3390/vaccines12121354 | PMID 39772016 Get It

Background/Objectives: Respiratory syncytial virus (RSV) causes symptoms similar to a mild cold for adults, but in case of infants, it causes bronchitis and/or pneumonia, and in some cases, mortality. Mucosal immunity within the respiratory tract includes tissue-resident memory T (TRM) cells and tissue-resident memory B (BRM) cells, which provides rapid and efficient protection against RSV re-infection. Therefore, vaccine strategies should aim to generate mucosal immune responses. However, the interactions between RSV vaccines and mucosal immune responses within the respiratory tract are poorly understood. We evaluated a mucosal immune system following immunization by RSV vaccine with poly-sorbitol transporter (RSV-PST), a nanoparticle adjuvant. Methods: We intranasally immunized the RSV-PST and identified the systemic and mucosal immune responses. Furthermore, we challenged with RSV A2 strain after immunization and investigated the protective effects. Results: Consequently, antigen-specific CD8+ TRM cells were markedly elevated in the lung parenchyma, yet exhibited impaired cytokine expression. In contrast, humoral immunity, with systemic antibody production from serum, but not in the respiratory tract, was significantly increased by RSV-PST immunization. Interestingly, the production of respiratory mucosal antigen-specific IgG after RSV A2 challenge dramatically increased in the bronchoalveolar lavage fluid (BALF) of the RSV-PST immunized group in the presence of FTY720, and the lung-infected RSV titer was significantly lower in this group. Furthermore, after RSV A2 challenge, CD69+ IgG+ BRM cells were significantly increased in lung tissues in the RSV-PST group. Conclusions: The RSV-PST vaccine has protective effects against RSV infection by promoting both systemic and local humoral immunity rather than cellular immunity.
Integrating patient advocacy groups in the development of clinical practice guidelines: comment on the article by Johnson et al
Carsons, Steven E. , Carteron, Nancy , Scofield, R. Hal , Lee, Augustine S. , Thomas, Donald E. , Moua, Teng , Clair, E. William St. , Meehan, Richard T. , Dunleavy, Kieron , Makara, Matt, Hammitt, Katherine M. , Meehan, Richard , Hammitt, Katherine Morland , Dunleavy, Kieron , Gupta, Nishant , Thomas, Donald E., Ussavarungsi, Kamonpun

Mayo Clinic

Arthritis Care & Research | November 28, 2024 | Volume: 77 | Issue: 5 | Pages: 685-686

10.1002/acr.25474 | PMID 39605233 Get It

Sex Differences in Patient-Reported Outcomes and Perception of Ascites Burden Among Outpatients With Decompensated Cirrhosis and Ascites
Wong, Florence , Reddy, K. Rajender , Tandon, Puneeta , Lai, Jennifer C. , García‐Tsao, Guadalupe , O'leary, Jacqueline, Biggins, Scott W. , Vargas, Hugo E. , Thacker, Leroy R. , Kamath, Patrick S. , Bajaj, Jasmohan S. , Group, The NACSELD III Study, O'Leary, Jacqueline G , Thacker, Leroy R , Tandon, Puneeta , Wong, Florence , Lai, Jennifer , Vargas, Hugo E , García–Tsao, Guadalupe , Group, The NACSELD III Study

Mayo Clinic

American Journal of Gastroenterology | November 27, 2024 | Volume: 120 | Issue: 8 | Pages: 1791-1799

10.14309/ajg.0000000000003251 | PMID 39601412 Get It

INTRODUCTION: Perception of the ascites burden and its effects on quality of life may be different between sexes. This study assessed sex differences in perception of ascites burden and its impact on health-related quality of life (HRQoL) in patients with recurrent or refractory ascites. METHODS: The North American Consortium for the Study of End-stage Liver Disease prospectively enrolled outpatients with cirrhosis and large ascites requiring repeat large volume paracenteses. Demographics, laboratory results, comorbidities, medications, frailty measurements, and self-reported questionnaires related to functional status, physical activities, and HRQoL (generic = Short Form 36 and ascites specific = Ascites Questionnaire) were compared between sexes. RESULTS: In total, 392 men (59.6 ± 10.7 years) and 184 women (59.5 ± 11.1 years) with predominantly alcohol-related liver disease (51% and 43%, respectively) and median Model for End-Stage Liver Disease-Na: 13 were enrolled. Both groups had similar comorbidities and cirrhosis complications, ascites duration and severity, and frailty scores ( P = 0.94). Women had more symptoms related to their ascites (Ascites Questionnaire score = 66 ± 21 vs 60 ± 21 in men, P = 0.001) (higher value = feeling worse). 35% of women felt depressed vs 22% of men ( P = 0.0009), with lower mental but not physical functioning components of Short Form 36 ( P = 0.019). Women continued to conduct their daily activities as adequately as men as indicated by Duke Status Activity Index ( P = 0.27) and Godin Leisure Activity Index ( P = 0.47). DISCUSSION: Women with cirrhosis and ascites experienced worse emotional HRQoL than men without difference in daily function. Our analyses underscore the differences in the lived experience of women vs men with cirrhosis and highlight the need for patient-reported metrics to provide patient-centered care.
Effectiveness and Safety of Hypofractionated Gamma Knife Radiosurgery for Large Meningiomas and Those Adjacent to the Optic Pathway and Brainstem: Preliminary Therapeutic Outcomes
Hirano, Yudai , Shinya, Yuki , Umekawa, Motoyuki , Kawashima, Mariko , Wipplinger, Tamara , Shinya, Yuki , Hasegawa, Hirotaka , Wipplinger, Christoph , Katano, Atsuto , Saito, Nobuhito

Mayo Clinic

No container title available | November 27, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5147270/v1 Get It

Abstract Background Recent technologic advancements have facilitated the use of hypofractionated Gamma Knife-based radiosurgery (HF-GKRS) to treat large lesions or those in eloquent areas. This study aimed to analyze the preliminary results of HF-GKRS for these meningiomas, and to determine its effectiveness and safety. Methods This single-center retrospective study analyzed data of patients who underwent HF-GKRS for large meningiomas or those in eloquent areas with > 6 months of follow-up. The primary outcome was progression-free survival (PFS). The secondary outcomes were neurological deterioration, post-treatment T2 signal changes following HF-GKRS, and tumor volume changes. Volumetric analysis of the tumors after treatment was also performed to assess changes in tumor size after HF-GKRS. Results Overall, 24 patients with a median follow-up period of 22 months (range: 6–49 months) were included. Among them, 18 (75%) patients had tumors in close proximity to the optic pathway, and 15 (63%) patients had large lesions (> 10 cm3). The cumulative 1- and 3-year PFS rates were 100% and 92%, respectively. The cumulative 3-year rate of adverse radiation effects was 9%. Overall, 12 patients (50%) showed tumor reduction, with a median tumor reduction rate of 45% (range: 25–58%). Conclusions Our preliminary results revealed that HF-GKRS for large meningiomas or those in eloquent areas is safe and effective, with satisfactory short- and mid-term PFS and low adverse radiation effects. Further research with more patients and longer follow-up periods is required.
Neurohospitalist Core Competencies
Wold, Jana , Robertson, Jetter , Jeevarajan, Jerome , Knox, Molly G., Thatikunta, Prateek , Solorzano, Guillermo E., Galetta, Kristin , Dujari, Shefali , Goyal, Tarini , Ehrlich, Matthew , Donnelly, J., Marriott, Elizabeth , Mandge, Vishal , Dhoot, Roshni , Luedke, Matthew W. , Maas, Matthew B., Yu, Mei , Tolédano, Michel B. , Palaganas, Jamie L., Kvam, Kathryn A. , Dugue, Rachelle , Meltzer, Ethan , Touma, Lahoud , Shah, Maulik , Douglas, Vanja C. , Orjuela, Karen , Klein, Joshua P. , Likosky, David, Simpson, Jennifer , Richie, Megan , Dohle, Carolin, Morris, Jane G. , Gold, Carl A. , Maas, Matthew B. , Wold, Jana J , Ehrlich, Matthew E , Mustafa, Rafid , Kvam, Kathryn , Meltzer, Ethan , Shah, Maulik P , Orjuela, Karen , Klein, Joshua P , Gold, Carl A , Yu, Margaret Y., Toledano, Michel, Mustafa, Rafid , Palaganas, Jamie, Scott, Brian J.

Mayo Clinic

The Neurohospitalist | November 26, 2024 | Volume: 15 | Issue: 1 | Pages: 13-84

10.1177/19418744241297187 | PMID 39610897 Get It

The Neurohospitalist Core Competencies comprise a set of competency-based learning objectives that encapsulate the knowledge, skills, and attitudes of neurohospitalitists who specialize in the care of hospitalized patients with neurologic conditions. These competencies serve to characterize the rapidly expanding field of neurohospitalist medicine. The 27 chapters are divided into 3 sections entitled: neurological conditions, clinical interventions and interpretation of ancillary studies, and neurohospitalist role in the healthcare system. Each individual learning objective in the chapters describes a specific concept with an action verb to illustrate the behavior that the neurohospitalist exhibits. The individual neurohospitalist may not exhibit mastery in each of the topics included as individual practices vary in scope and practice pattern. A few examples of how the complete set of competencies may be used include in the creation of curricula for neurohospitalist fellowships, to assist in defining the scope of practice of neurohospitalists for administrative leaders of hospitals and departments, and in influencing the direction of further research and quality improvement in the field.